AC 105

Drug Profile

AC 105

Alternative Names: AC-105; PEG-magnesium; Pegylated-magnesium; Polyethylene-glycol-magnesium

Latest Information Update: 06 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medtronic
  • Developer Acorda Therapeutics
  • Class Magnesium compounds; Neuroprotectants; Polyethylene glycols
  • Mechanism of Action Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 01 May 2015 Acorda Therapeutics completes a phase II trial in Spinal cord injuries in USA and Canada (NCT01750684)
  • 01 Feb 2015 Acorda Therapeutics terminates its licensing agreement with Medtronic (Acorda Therapeutics 10-K, February 2015)
  • 17 Jul 2013 Phase-II clinical trials in Spinal cord injuries in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top